In recent years, the global pharmaceutical and health industry has undergone earth-shaking changes. Aging populations, increasing chronic diseases, surging demand from emerging markets, and the global impact of the COVID-19 pandemic are all driving rapid industry development and transformation. In this era full of opportunities and challenges, China’s biomedical and medical device enterprises are standing at the crossroads of globalization, facing unprecedented development opportunities.
In this context, Chinese companies are expected to play a more important role on the global stage with their advantages in innovation, manufacturing and market scale. However, the road to globalisation has not been smooth. Many challenges, such as complex regulatory environment, fierce market competition and intellectual property protection, require Chinese companies to respond prudently. How to enter the target market quickly while ensuring compliance? How to adopt the right model to go to sea in order to find their position in the global healthcare value chain? These are all important issues in front of China’s pharmaceutical equipment enterprises.
This white paper aims to provide a comprehensive guide for Chinese biopharmaceutical and medical device companies on their global journey. We provide an in-depth analysis of the current status and trends of the global pharmaceutical and health industry, as well as the overseas trend of Chinese companies in recent years, with a focus on the opportunities and challenges in key markets such as Europe, the United States, Japan, Southeast Asia and the Middle East. Through a detailed understanding of the regulatory environment, market characteristics and access strategies in each region, we hope to help Chinese companies better grasp international opportunities and avoid potential risks. We believe that multinational pharmaceutical companies as well as emerging biotech companies will find valuable insights and advice in this white paper.